Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants

被引:15
|
作者
Chandrashekar, Abishek [1 ]
Liu, Jinyan [1 ]
Yu, Jingyou [1 ]
McMahan, Katherine [1 ]
Tostanoski, Lisa H. [1 ]
Jacob-Dolan, Catherine [1 ,2 ]
Mercado, Noe B. [1 ]
Anioke, Tochi [1 ]
Chang, Aiquan [1 ,2 ]
Gardner, Sarah [1 ]
Giffin, Victoria M. [1 ]
Hope, David L. [1 ]
Nampanya, Felix [1 ]
Patel, Shivani [1 ]
Sanborn, Owen [1 ]
Sellers, Daniel [1 ]
Wan, Huahua [1 ]
Martinot, Amanda J. [3 ]
Baczenas, John J. [4 ,5 ]
O'Connor, Shelby L. [4 ,5 ]
Pessaint, Laurent [6 ]
Valentin, Daniel [6 ]
Espina, Benjamin [6 ]
Wattay, Lauren [6 ]
Ferrari, Maria G. [6 ]
Brown, Renita [6 ]
Cook, Anthony [6 ]
Bueno-Wilkerson, Deandre [6 ]
Teow, Elyse [6 ]
Andersen, Hanne [6 ]
Lewis, Mark G. [6 ]
Barouch, Dan H. [1 ,2 ,7 ]
机构
[1] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Tufts Univ, Cummings Sch Vet Med, North Grafton, MA 01536 USA
[4] Wisconsin Natl Primate Res Ctr, Madison, WI 53711 USA
[5] Univ Wisconsin, Madison, WI 53711 USA
[6] BIOQUAL, Rockville, MD 20852 USA
[7] MIT & Harvard, Ragon Inst MGH, Cambridge, MA 02139 USA
基金
美国国家卫生研究院; 比尔及梅琳达.盖茨基金会;
关键词
D O I
10.1126/scitranslmed.abj2641
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that result in increased transmissibility and partial evasion of neutralizing antibodies have recently emerged. Whether natural immunity induced by the original SARS-CoV-2 WA1/2020 strain protects against rechallenge with these SARS-CoV-2 variants remains a critical unresolved question. In this study, we show that natural immunity induced by the WA1/2020 strain leads to partial but incomplete protection against the SARS-CoV-2 variants B.1.1.7 (alpha) and B.1.351 (beta) in rhesus macaques. We challenged rhesus macaques with B.1.1.7 and B.1.351 and showed that infection with these variants resulted in high viral replication in the upper and lower respiratory tract. We then infected rhesus macaques with the WA1/2020 strain and rechallenged them on day 35 with the WA1/2020, B.1.1.7, or B.1.351 variants. Natural immunity to WA1/2020 led to robust protection against rechallenge with WA1/2020 but only partial protection against rechallenge with B.1.351. An intermediate degree of protection was observed in rhesus macaques against rechallenge with B.1.1.7. These data demonstrate partial but incomplete protective efficacy of natural immunity induced by WA1/2020 against SARS-CoV-2 variants of concern. Our findings have important implications for both vaccination and public health strategies in the context of emerging SARS-CoV-2 variants of concern.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Direct RT-qPCR assay for SARS-CoV-2 variants of concern (Alpha, B.1.1.7 and Beta, B.1.351) detection and quantification in wastewater
    Yaniv, Karin
    Ozer, Eden
    Shagan, Marilou
    Lakkakula, Satish
    Plotkin, Noam
    Bhandarkar, Nikhil Suresh
    Kushmaro, Ariel
    ENVIRONMENTAL RESEARCH, 2021, 201
  • [22] Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
    Shen, Xiaoying
    Tang, Haili
    Pajon, Rolando
    Smith, Gale
    Glenn, Gregory M.
    Shi, Wei
    Korber, Bette
    Montefiori, David C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (24): : 2352 - 2354
  • [23] Multiple partition Markov model for B.1.1.7, B.1.351, B.1.617.2, and P.1 variants of SARS-CoV 2 virus
    Garcia, Jesus Enrique
    Gonzalez-Lopez, Veronica Andrea
    Tasca, Gustavo Henrique
    COMPUTATIONAL STATISTICS, 2022,
  • [24] The SARS-CoV-2 B.1.351 lineage (VOC β) is outgrowing the B.1.1.7 lineage (VOC α) in some French regions in April 2021
    Roquebert, Benedicte
    Trombert-Paolantoni, Sabine
    Haim-Boukobza, Stephanie
    Lecorche, Emmanuel
    Verdurme, Laura
    Fouliongne, Vincent
    Sofonea, Mircea T.
    Alizon, Samuel
    EUROSURVEILLANCE, 2021, 26 (23)
  • [25] Comparison of SARS-CoV-2 Variants of Concern Alpha (B.1.1.7) vs. Beta (B.1.351) in Critically Ill Patients: A Multicenter Cohort Study
    Louis, Guillaume
    Belveyre, Thibaut
    Goetz, Christophe
    Gibot, Sebastien
    Dunand, Paul
    Conrad, Marie
    Gaci, Rostane
    Gette, Sebastien
    Ouamara, Nadia
    Perez, Pascale
    Cadoz, Cyril
    Picard, Yoann
    Mellati, Nouchan
    FRONTIERS IN MEDICINE, 2022, 9
  • [26] Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021
    Funk, Tjede
    Pharris, Anastasia
    Spiteri, Gianfranco
    Bundle, Nick
    Melidou, Angeliki
    Carr, Michael
    Gonzalez, Gabriel
    Garcia-Leon, Alejandro
    Crispie, Fiona
    O'Connor, Lois
    Murphy, Niamh
    Mossong, Joel
    Vergison, Anne
    Wienecke-Baldacchino, Anke K.
    Abdelrahman, Tamir
    Riccardo, Flavia
    Stefanelli, Paola
    Di Martino, Angela
    Bella, Antonino
    Lo Presti, Alessandra
    Casaca, Pedro
    Moreno, Joana
    Borges, Vitor
    Isidro, Joana
    Ferreira, Rita
    Gomes, Joao Paulo
    Dotsenko, Liidia
    Suija, Heleene
    Epstein, Jevgenia
    Sadikova, Olga
    Sepp, Hanna
    Ikonen, Niina
    Savolainen-Kopra, Carita
    Blomqvist, Soile
    Mottonen, Teemu
    Helve, Otto
    Gomes-Dias, Joana
    Adlhoch, Cornelia
    EUROSURVEILLANCE, 2021, 26 (16)
  • [27] Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
    Abu-Raddad, Laith J.
    Chemaitelly, Hiam
    Butt, Adeel A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (02): : 187 - 189
  • [28] Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020-May 2021
    Veneti, Lamprini
    Seppala, Elina
    Storm, Margrethe Larsdatter
    Salamanca, Beatriz Valcarcel
    Buanes, Eirik Alnes
    Aasand, Nina
    Naseer, Umaer
    Bragstad, Karoline
    Hungnes, Olav
    Boas, Hakon
    Kvale, Reidar
    Golestani, Karan
    Feruglio, Siri
    Vold, Line
    Nygard, Karin
    Whittaker, Robert
    PLOS ONE, 2021, 16 (10):
  • [29] Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications
    Singh, Jasdeep B.
    Samal, Jasmine
    Kumar, Vipul
    Sharma, Jyoti
    Agrawal, Usha
    Ehtesham, Nasreen Z.
    Sundar, Durai
    Rahman, Syed Asad
    Hira, Subhash
    Hasnain, Seyed E.
    VIRUSES-BASEL, 2021, 13 (03):
  • [30] A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351
    Gu, Chunyin
    Cao, Xiaodan
    Wang, Zongda
    Hu, Xue
    Yao, Yanfeng
    Zhou, Yiwu
    Liu, Peipei
    Liu, Xiaowu
    Gao, Ge
    Hu, Xiao
    Zhang, Yecheng
    Chen, Zhen
    Gao, Li
    Peng, Yun
    Jia, Fangfang
    Shan, Chao
    Yu, Li
    Liu, Kunpeng
    Li, Nan
    Guo, Weiwei
    Jiang, Guoping
    Min, Juan
    Zhang, Jianjian
    Yang, Lu
    Shi, Meng
    Hou, Tianquan
    Li, Yanan
    Liang, Weichen
    Lu, Guoqiao
    Yang, Congyi
    Wang, Yuting
    Xia, Kaiwen
    Xiao, Zheng
    Xue, Jianhua
    Huang, Xueyi
    Chen, Xin
    Ma, Haixia
    Song, Donglin
    Pan, Zhongzong
    Wang, Xueping
    Guo, Haibing
    Liang, Hong
    Yuan, Zhiming
    Guan, Wuxiang
    Deng, Su-Jun
    MABS, 2021, 13 (01)